Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment

Investigator: Pamela Munster, MD
Sponsor: Nektar Therapeutics

Location(s): United States


The purpose of this study is to investigate the PK and safety of NKTR-102 in patients with mild or moderate hepatic impairment.  Safety and PK data from patients with mild or moderate hepatic impairment will be compared with a control group consisting of patients with normal hepatic function.